Related Experiment Videos

Dying-back oligodendrogliopathy: a late sequel of myelin-associated glycoprotein deficiency

H Lassmann1, U Bartsch, D Montag

  • 1Institute of Neurology, University of Vienna, Austria.

Glia
|February 1, 1997
PubMed

Insights

Mice lacking myelin-associated glycoprotein showed abnormal oligodendrocyte processes, resembling "dying-back oligodendrogliopathy" seen in demyelinating diseases like multiple sclerosis.

Area of Science:

  • Neuroscience
  • Cell Biology
  • Demyelinating Diseases

Background:

  • Myelin-associated glycoprotein (MAG) plays a role in myelin maintenance.
  • Oligodendrocytes are glial cells responsible for myelinating axons in the central nervous system.
  • Dying-back oligodendrogliopathy is a pathological process observed in various demyelinating conditions.

Purpose of the Study:

  • To investigate the ultrastructural consequences of myelin-associated glycoprotein deficiency in oligodendrocytes.
  • To compare the observed alterations with known patterns of dying-back oligodendrogliopathy.

Main Methods:

  • Ultrastructural analysis using electron microscopy.
  • Examination of periaxonal oligodendrocyte processes in 8-month-old mice genetically deficient in MAG.

Main Results:

  • Mice deficient in MAG exhibited significant alterations in periaxonal oligodendrocyte processes.
  • These alterations included intracytoplasmic deposition of vesicular material, multivesicular bodies, mitochondria, and lipofuscin granules.
  • Granular or paracrystalline inclusions were also observed within the oligodendrocyte processes.

Conclusions:

  • MAG deficiency leads to characteristic ultrastructural changes in oligodendrocytes.
  • These changes mirror the pathology of dying-back oligodendrogliopathy.
  • This suggests a potential role for MAG in oligodendrocyte health and myelin integrity, relevant to diseases like multiple sclerosis.

Related Concept Videos